Inhibition of inflammatory and neuropathic pain by targeting a Mu opioid receptor/chemokine receptor5 heteromer (MOR-CCR5)

Journal of Medicinal Chemistry

Volumn 58, Issue 21, 2015, Pages 8647-8657

  Akgün, Eyup ^a   Javed, Muhammad I ^a   Lunzer, Mary M ^a   Powers, Michael D ^a   Sham, Yuk Y ^b   Watanabe, Yoshikazu ^a   Portoghese, Philip S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; LIPOPOLYSACCHARIDE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; ANALGESIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; INFLAMMATION; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PHARMACOPHORE; AGONISTS; ANIMAL; CHEMISTRY; CHRONIC DISEASE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NEURALGIA;

ANALGESICS; ANIMALS; CCR5 RECEPTOR ANTAGONISTS; CHRONIC DISEASE; HEK293 CELLS; HUMANS; INFLAMMATION; MALE; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEURALGIA; RECEPTORS, CCR5; RECEPTORS, OPIOID, MU;

EID: 84947483857     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01245     Document Type: Article

References (64)

1. Reuben, D. B.; Alvanzo, A. A. H.; Ashikaga, T.; Bogat, G. A.; Callahan, C. M.; Ruffing, V.; Steffens, D. C. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain Ann. Intern. Med. 2015, 162, 295-300 10.7326/M14-2775
2. Chou, R.; Turner, J. A.; Devine, E. B.; Hansen, R. N.; Sullivan, S. D.; Blazina, I.; Dana, T.; Bougatsos, C.; Deyo, R. A. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop Ann. Intern. Med. 2015, 162, 276-286 10.7326/M14-2559
3. Parsadaniantz, S. M.; Rivat, C.; Rostene, W.; Goazigo, A. R.-L. Opioid and chemokine receptor crosstalk: a promising target for pain therapy Nat. Rev. Neurosci. 2015, 16, 69-78 10.1038/nrn3858
4. Hutchinson, M. R.; Shavit, Y.; Grace, P. M.; Rice, K. C.; Maier, S. F.; Watkins, L. R. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia Pharmacol. Rev. 2011, 63, 772-810 10.1124/pr.110.004135
5. Schwarz, J. M.; Hutchinson, M. R.; Bilbo, S. D. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression J. Neurosci. 2011, 31, 17835-17847 10.1523/JNEUROSCI.3297-11.2011
6. Milligan, E. D.; Watkins, L. R. Pathological and protective roles of glia in chronic pain Nat. Rev. Neurosci. 2009, 10, 23-36 10.1038/nrn2533
7. Lee, C. W.-S.; Ho, I.-K. Pharmacological profiles of oligomerized μ-opioid receptors Cells 2013, 2, 689-714 10.3390/cells2040689
8. 5 heteromer in mice with inflammatory pain produce potent antinociception Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 11595-11599 10.1073/pnas.1305461110
9. Smeester, B. A.; Lunzer, M. M.; Akgun, E.; Beitz, A. J.; Portoghese, P. S. Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model Eur. J. Pharmacol. 2014, 743, 48-52 10.1016/j.ejphar.2014.09.008
10. Lee, Y. K.; Choi, D.-Y.; Jung, Y.-Y.; Yun, Y. W.; Lee, B. J.; Han, S. B.; Hong, J. T. Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli Neuropharmacology 2013, 67, 57-65 10.1016/j.neuropharm.2012.10.030
11. Rogers, T. J.; Peterson, P. K. Opioid G protein-coupled receptors: signals at the crossroads of inflammation Trends Immunol. 2003, 24, 116-121 10.1016/S1471-4906(03)00003-6
12. Mahajan, S. D.; Schwartz, S. A.; Aalinkeel, R.; Chawda, R. P.; Sykes, D. E.; Nair, M. P. N. Morphine modulates chemokine gene regulation in normal human astrocytes Clin. Immunol. (Amsterdam, Neth.) 2005, 115, 323-332 10.1016/j.clim.2005.02.004
13. Happel, C.; Steele, A. D.; Finley, M. J.; Kutzler, M. A.; Rogers, T. J. DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-β1 J. Leukocyte Biol. 2008, 83, 956-963 10.1189/jlb.1007685
14. 5 on immune cells Exp. Cell Res. 2002, 280, 192-200 10.1006/excr.2002.5638
15. 5 receptor Eur. J. Pharmacol. 2004, 483, 175-186 10.1016/j.ejphar.2003.10.033
16. Weiss, U. Derivatives of morphine. I. 14-Hydroxydihydromorphinone J. Am. Chem. Soc. 1955, 77, 5891-5892 10.1021/ja01627a033
17. 5 antagonist Antimicrob. Agents Chemother. 2005, 49, 3474-3482 10.1128/AAC.49.8.3474-3482.2005
18. Le Naour, M.; Akgün, E.; Yekkirala, A.; Lunzer, M. M.; Powers, M. D.; Kalyuzhny, A. E.; Portoghese, P. S. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance J. Med. Chem. 2013, 56, 5505-5513 10.1021/jm4005219
19. Zheng, Y.; Akgün, E.; Harikumar, K. G.; Hopson, J.; Powers, M. D.; Lunzer, M. M.; Miller, L. J.; Portoghese, P. S. Induced association of μ opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands J. Med. Chem. 2009, 52, 247-258 10.1021/jm800174p
20. Xie, Z.; Bhushan, R. G.; Daniels, D. J.; Portoghese, P. S. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells Mol. Pharmacol. 2005, 68, 1079-1086 10.1124/mol.105.012070
21. Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 2004, 47, 2969-2972 10.1021/jm0342358
22. Daniels, D. J.; Kulkarni, A.; Xie, Z.; Bhushan, R. G.; Portoghese, P. S. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes J. Med. Chem. 2005, 48, 1713-1716 10.1021/jm034234f
23. Zhang, S.; Yekkirala, A.; Tang, Y.; Portoghese, P. S. A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors Bioorg. Med. Chem. Lett. 2009, 19, 6978-6980 10.1016/j.bmcl.2009.10.045
24. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P. Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 19208-19213 10.1073/pnas.0506627102
25. Calil, I. L.; Zarpelon, A. C.; Guerrero, A. T. G.; Alves-Filho, J. C.; Ferreira, S. H.; Cunha, F. Q.; Cunha, T. M.; Verri, W. A. Lipopolysaccharide induces inflammatory hyperalgesia triggering a TLR4/MyD88-dependent cytokine cascade in the mice paw PLoS One 2014, 9, e90013/1-e90013/8 10.1371/journal.pone.0090013
26. Takemori, A. E.; Larson, D. L.; Portoghese, P. S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone Eur. J. Pharmacol. 1981, 70, 445-451 10.1016/0014-2999(81)90355-1
27. Yoon, S. Y.; Patel, D.; Dougherty, P. M. Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes Neuroscience (Amsterdam, Neth.) 2012, 221, 214-224 10.1016/j.neuroscience.2012.06.024
28. Watkins, L. R.; Hutchinson, M. R.; Johnston, I. N.; Maier, S. F. Glia: Novel counter-regulators of opioid analgesia Trends Neurosci. 2005, 28, 661-669 10.1016/j.tins.2005.10.001
29. Vallejo, R.; Tilley, D. M.; Vogel, L.; Benyamin, R. The role of glia and the immune system in the development and maintenance of neuropathic pain Pain Pract. 2010, 10, 167-184 10.1111/j.1533-2500.2010.00367.x
30. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature (London, U. K.) 2012, 485, 321-326 10.1038/nature10954
31. 5 chemokine receptor-HIV entry inhibitor Maraviroc complex Science (Washington, DC, U. S.) 2013, 341, 1387-1390 10.1126/science.1241475
32. 5 antagonists Mol. Pharmacol. 2008, 73, 789-800 10.1124/mol.107.042101
33. 5 Antimicrob. Agents Chemother. 2005, 49, 4708-4715 10.1128/AAC.49.11.4708-4715.2005
34. Abbadie, C. Chemokines, chemokine receptors and pain Trends Immunol. 2005, 26, 529-534 10.1016/j.it.2005.08.001
35. Takaki, J.; Fujimori, K.; Miura, M.; Suzuki, T.; Sekino, Y.; Sato, K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the 'collusion' hypothesis for increased extracellular L-glutamate concentration in neuroinflammation J. Neuroinflammation 2012, 9, 275-292 10.1186/1742-2094-9-275
36. Mousa, S. A.; Machelska, H.; Schafer, M.; Stein, C. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain J. Neuroimmunol. 2002, 126, 5-15 10.1016/S0165-5728(02)00049-8
37. Morinville, A.; Cahill, C. M.; Kieffer, B.; Collier, B.; Beaudet, A. Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain Pain 2004, 109, 266-273 10.1016/j.pain.2004.01.011
38. Ballet, S.; Conrath, M.; Fischer, J.; Kaneko, T.; Hamon, M.; Cesselin, F. Expression and G-protein coupling of mu-opioid receptors in the spinal cord and dorsal root ganglia of polyarthritic rats Neuropeptides 2003, 37, 211-219 10.1016/S0143-4179(03)00045-3
39. Zaringhalam, J.; Manaheji, H.; Mghsoodi, N.; Farokhi, B.; Mirzaiee, V. Spinal μ-opioid receptor expression and hyperalgesia with dexamethasone in chronic adjuvant-induced arthritis in rats Clin. Exp. Pharmacol. Physiol. 2008, 35, 1309-1315 10.1111/j.1440-1681.2008.05009.x
40. Puehler, W.; Zoellner, C.; Brack, A.; Shaqura, M. A.; Krause, H.; Schaefer, M.; Stein, C. Rapid upregulation of μ opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction Neuroscience (Amsterdam, Neth.) 2004, 129, 473-479 10.1016/j.neuroscience.2004.06.086
41. Shaqura, M. A.; Zoellner, C.; Mousa, S. A.; Stein, C.; Schaefer, M. Characterization of μ opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain J. Pharmacol. Exp. Ther. 2004, 308, 712-718 10.1124/jpet.103.057257
42. Singh, M.; Singh, P.; Vaira, D.; Amand, M.; Rahmouni, S.; Moutschen, M. Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγnull mice Immunology 2014, 142, 562-572 10.1111/imm.12246
43. Sham, Y. Y.; Lunzer, M. M.; Powers, M. D.; Javed, M. I.; Cataldo, G.; Simone, D. A.; Akgün, E.; Portoghese, P. S. Modeling and Simulation of MCC22, a Bivalent Ligand That Potently Inhibits Inflammatory and Neuropathic Pain in Mice. Computer Aided Drug Design; Gorden Research Conferance, Mount Snow, VT, Jul 19-24, 2015.
44. Akgün, E.; Javed, M. I.; Lunzer, M. M.; Powers, M. D.; Sham, Y. Y.; Portoghese, P. S. MCC22 Targets Putative Spinal MOR-CCR5 Heteromers in a Mouse Model of Inflammatory Pain (MEDI 534); ACS 250th National Meeting, Boston, MA, Aug 16-19, 2015; American Chemical Society: Washington, DC.
45. Portoghese, P. S.; Lunzer, M. M.; Powers, M. D.; Javed, M. I.; Sham, Y. K.; Cataldo, G.; Simone, D. A.; Akgun, E. A Bivalent Ligand (MCC22) Potently Inhibits Inflammatory and Neuropathic Pain via Putative MOR-CCR5 Heteromers in Mouse Spinal Cord; 46th Meeting of the International Narcotics Research Conference in conjunction with the 77th Annual College on Problems of Drug Dependence, Phoenix, AZ, Jun 15-19, 2015.
46. Imamura, S.; Ichikawa, T.; Nishikawa, Y.; Kanzaki, N.; Takashima, K.; Niwa, S.; Iizawa, Y.; Baba, M.; Sugihara, Y. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity J. Med. Chem. 2006, 49, 2784-2793 10.1021/jm051034q
47. 2) Receptor by Novel Bivalent Ligands; XXth International Symposium on Medicinal Chemistry, Vienna, Austria, Aug 31-Sep 4, 2008.
48. Sayre, L. M.; Portoghese, P. S. Stereospecific synthesis of the 6α- and 6β-amino derivatives of naltrexone and oxymorphone J. Org. Chem. 1980, 45, 3366-3368 10.1021/jo01304a051
49. Daniels, D. J. Bivalent Ligands as Probes for the Investigation of Opioid Receptor Dimerization. Ph.D. Thesis, University of Minnesota, Minneapolis, MN. 2006.
50. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation J. Pharmacol. Exp. Ther. 1941, 72, 74-79
51. Dewey, W. L.; Harris, L. S.; Howes, J. F.; Nuite, J. A. Effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests J. Pharmacol. Exp. Ther. 1970, 175, 435-442
52. Harris, L. S.; Pierson, A. K. Narcotic antagonists in the benzomorphan series J. Pharmacol. Exp. Ther. 1964, 143, 141-148
53. Hylden, J. L.; Wilcox, G. L. Intrathecal morphine in mice: A new technique Eur. J. Pharmacol. 1980, 67, 313-316 10.1016/0014-2999(80)90515-4
54. Wade, C. L.; Krumenacher, P.; Kitto, K. F.; Peterson, C. D.; Wilcox, G. L.; Fairbanks, C. A. Effect of chronic pain on fentanyl self-administration in mice PLoS One 2013, 8, e79239/1-e79239/11 10.1371/journal.pone.0079239
55. Sorge, R. E.; LaCroix-Fralish, M. L.; Tuttle, A. H.; Sotocinal, S. G.; Austin, J.-S.; Ritchie, J.; Chanda, M. L.; Graham, A. C.; Topham, L.; Beggs, S.; Salter, M. W.; Mogil, J. S. Spinal cord Toll-like receptor 4 mediates inflammatory and neuropathic hypersensitivity in male but not female mice J. Neurosci. 2011, 31, 15450-15454 10.1523/JNEUROSCI.3859-11.2011
56. Schrodinger Modeling Suite Package: Maestro, Biolumintate, Glide, Prime, Macromodel, Liaison, Strike, Jaguar; Schrödinger LLC: New York, NY, 2013.
57. Wilson, D. J.; Shi, C.; Duckworth, B. P.; Muretta, J. M.; Manjunatha, U.; Sham, Y. Y.; Thomas, D. D.; Aldrich, C. C. A continuous fluorescence displacement assay for BioA: An enzyme involved in biotin biosynthesis Anal. Biochem. 2011, 416, 27-38 10.1016/j.ab.2011.05.003
58. Zhang, Y.; Sham, Y. Y.; Rajamani, R.; Gao, J.; Portoghese, P. S. Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system ChemBioChem 2005, 6, 853-859 10.1002/cbic.200400207
59. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236 10.1021/ja9621760
60. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics J. Am. Chem. Soc. 1990, 112, 6127-6129 10.1021/ja00172a038
61. Dror, R. O.; Green, H. F.; Valant, C.; Borhani, D. W.; Valcourt, J. R.; Pan, A. C.; Arlow, D. H.; Canals, M.; Lane, J. R.; Rahmani, R.; Baell, J. B.; Sexton, P. M.; Christopoulos, A.; Shaw, D. E. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 2013, 503, 295-299 10.1038/nature12595
62. Nygaard, R.; Zou, Y.; Dror, R. O.; Mildorf, T. J.; Arlow, D. H.; Manglik, A.; Pan, A. C.; Liu, C. W.; Fung, J. J.; Bokoch, M. P.; Thian, F. S.; Kobilka, T. S.; Shaw, D. E.; Mueller, L.; Prosser, R. S.; Kobilka, B. K. The dynamic process of β2-adrenergic receptor activation Cell 2013, 152, 532-542 10.1016/j.cell.2013.01.008
63. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935 10.1063/1.445869
64. Desmond Molecular Dynamics System, v3.0; D. E. Shaw Research: New York, NY, 2011.